



ASX Release
29 January 2026

Compumedics secures another new \$4.2 million MEG sales order in key China growth market

New China order strengthens MEG order book and extends revenue visibility into FY27

Highlights

- New \$4.2 million MEG sales order from Shandong Normal University, China
- Sixth Orion LifeSpan™ MEG system order secured, taking total MEG contracted orders to approximately \$30 million
- Reinforces Compumedics' leadership position in the global MEG market, one of the most complex and high-value segments of neuro-imaging
- Order adds to an expanding MEG order book supporting revenue delivery through FY27
- China continues to demonstrate strong demand momentum, with additional MEG opportunities progressing globally

Compumedics Limited (ASX: CMP) ("Compumedics" or "Company") is pleased to announce that it has secured a new approximately \$4.2 million sales order for its Orion LifeSpan™ magnetoencephalography (MEG) system from Shandong Normal University (SDNU) in China.

The order, placed via Beijing Fistar, Compumedics' long-standing Chinese distributor for neuro-imaging systems, represents the Company's sixth MEG system sale and takes total contracted MEG orders to approximately \$30 million.

The MEG system will be delivered in line with established production and site-readiness timelines, with revenue contribution expected in FY27. The contract includes the Orion LifeSpan™ dual-helmet adult and paediatric MEG platform, integrated CURRY neuro-imaging software and associated peripherals.

Strategic Significance

MEG systems represent one of the highest-value and most technically demanding modalities in global brain imaging, with a very limited number of credible suppliers worldwide. This latest order further validates Compumedics' technological leadership and commercial execution in a market characterised by long sales cycles, high barriers to entry and strong institutional demand.

For personal use only

China continues to emerge as a key growth market for advanced neuroscience research infrastructure, with Compumedics benefiting from a growing installed base, increasing reference sites and a deepening pipeline of MEG opportunities.

With multiple MEG systems now contracted and in various stages of production and delivery, the Company's MEG order book provides clear near and medium-term revenue visibility, complementing the broader momentum across Compumedics' sleep, neuro and SaaS platforms.

Investor Outlook

Compumedics' MEG business continues to scale, supporting a pathway to sustainable growth through high-value, contracted MEG system sales. With this sixth order secured, the Company's MEG contracted order book now extends revenue visibility well into FY27, with additional opportunities being pursued across China, North America and Europe. The Company expects MEG revenue recognition to continue to reflect production, delivery and installation timing, with milestone payments received across the project lifecycle.



Compumedics Global Neuro-Imaging Business Director, Gordon Haid said:

"Securing a sixth MEG order reflects both the growing maturity of the Orion LifeSpan™ platform and the increasing confidence of leading research institutions in Compumedics' technology. Demand in China remains strong, and we continue to see active MEG opportunities developing internationally."

Compumedics Executive Chairman, David Burton said:

"This is another significant commercial milestone for Compumedics. The Shandong Normal University order further validates the strategic value of our MEG business, which delivers large contract values, strong differentiation and long-term revenue visibility. With six systems now sold and further opportunities progressing, we believe Compumedics is well positioned to continue scaling this unique global neuro-imaging platform."

About Compumedics Neuroscan Orion LifeSpan™ MEG

MEG is a functional neuroimaging technique for mapping brain activity by recording magnetic fields produced by electrical currents occurring naturally in the brain using very sensitive detectors. Compumedics has revolutionised MEG with the Orion LifeSpan™'s increased precision coupled with fully integrated CURRY brain analysis software. Over a 30-year period Compumedics has established the gold standard in neurophysiological multi-modality (including MEG, EEG, MRI, CT, SPECT, PET) brain analysis software. In parallel, over a 30-year period our technology partner, the KRISS MEG team led by Dr. Yong-Ho Lee, have produced the most advanced MEG brain imaging scanner.

At the heart of the Orion LifeSpan™ are MEG sensors based on Double Relaxation Oscillation Superconducting Quantum Interference Devices (DROS SQUIDs), which are patented and exclusive. They are significantly more accurate than conventional MEG sensors.

Additionally, a unique dual-helmet dewar enables accurate measurements from adult and paediatric populations, along with hyperscanning. This includes a sensors-in-vacuum cooling system for more sensitive measurements. The dewar is coupled to a virtual 100% coolant recycling system with continuous operation. No refilling of helium is required and 24/7 operation is possible.

About Compumedics Limited

Compumedics Limited [ASX: CMP] is a leading global medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns Neuroscan, based in the USA, and DWL Elektronische Systeme GmbH, based in Germany. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. The same year, the Company successfully designed and installed the first fully computerised Australian sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on developing products for the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia's Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.

For further information, please contact:

Dr. David Burton

Executive Chairman, CEO

P: +61 3 8420 7300

F: +61 3 8420 7399

David Lawson

Director, CFO

P: +61 3 8420 7300

F: +61 3 8420 7399

Authorised for lodgement by Compumedics Limited's Board of Directors